Merck is about to perform post-marketing safety study of HPBCD-containing PREVYMIS™ injection
Merck Sharp and Dohme LLC. has received initial U.S. Approval: 2017 PREVYMIS™ (letermovir) injection, for intravenous use. In the first
Tag: prevymis